Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: Enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies

Blood

Volumn 85, Issue 4, 1995, Pages 917-924

  Montero Julian, Felix A ^b   Klein, Bernard ^b   Gautherot, Emmanuel ^b   Brailly, Hervé ^a  

^a Immunotech   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ANTIBODY; INTERLEUKIN RECEPTOR; MONOCLONAL ANTIBODY AH64; MONOCLONAL ANTIBODY AH65; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; DRUG BINDING; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TISSUE DISTRIBUTION;

EID: 0028900662     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v85.4.917.bloodjournal854917     Document Type: Article

References (49)

1. VanSnick J: Interleukin-6: An overview. Annu Rev Immunol 8:253, 1990
2. Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of interleukin 6, Immunol Today 11:443, 1990
3. Kishimoto T: The biology of interleukin 6. Blood 74:1, 1989
4. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaodu H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generationand requirement of BSF-2/IL-6 for human myeloma cells. Nature 332:83, 1988
5. Klein B, Zhang XG, Jourdan M, Content J, Houssiau J, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differenciation by interleukin 6. Blood 73:517, 1989
6. Vink A, Coulie P, Warnier G, Renauld J-C, Stevens M, Donckers D, VanSnick J: Mouse plasmacytoma growth in vivo: Enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against interleukin 6 or its receptor. J Exp Med 172:997, 1990
7. Miles SA, Rezai AR, Salazar-Gonzlez JF, Van Der Meyden M, Stevens MH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T, Martinez-Maza O: AIDS-Kaposi sarcoma-derived cells produce and respond to interleukin-6. Proc Natl Acad Sci USA 87:4068, 1990
8. Jilka RS, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC: Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257:88, 1992
9. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T: Interleukin-6 (IL-6) functions as an in vitro growth factor in renal cell carcinoma. FEBS Lett 250:607, 1989
10. Siegall CB, Schwab G, Nordan RP, Fitzgerald DJ, Pastan I: Expression of the interleukin-6 receptor and interleukin-6 in prostate carcinoma cells. Cancer Res 50:7786, 1990
11. Suzuki H, Yasukawa K, Anzai M, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T: Anti-murine IL-6 receptor antibody inhibits IL-6 effects in vivo. Immunol Lett 30:17, 1991
12. Yoneda T, Nakai M, Moriyama K, Scott L, Ida N, Kunitomo T, Mundy GR: Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res 53:737, 1993
13. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu ZY, Mannoni P, Sany J, Bataille R: Murine anti-interleukin 6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78:1228, 1991
14. Wendling D, Racadot E, Wijdenes J: Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibodies. J Rheumatol 22:259, 1993
15. Heinrich PC, Castell PV, Andus T: Interleukin-6 and the acute phase response. Biochemistry 265:622, 1990
16. Klein B, Lu ZY, Gaillard JP, Harousseau JL, Bataille R: Inhibiting IL-6 in human multiple myeloma. Curr Top Microbiol Immunol 182:237, 1992
17. Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B: High amounts of circulating immune interleukin-6 (IL-6) in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 22:2822, 1992
18. Mihara M, Koishihara Y, Fukui H, Yasukawa K, Ohsugi Y: Murine anti-human IL-6 monoclonal antibody prolongs the half life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Immunology 74:55, 1991
19. Martens E, Dillen C, Put W, Heremans H, VanDamme J, Billiau A: Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes. Eur J Immunol 23:2226, 1993
20. Wijdenes J, Clement C, Klein B, Morel-Fourrier B, Vita N, Ferrara P, Peters A: Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies. Mol Immunol 28:1183, 1991
21. Unkeless JC: Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptor. J Exp Med 150:580, 1978
22. Covell DG, Barbet J, Holton OD, Black CDV, Parker RJ, Weinstein JN: Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2 and Fab′ in mice. Cancer Res 46:3969, 1986
23. Webster WB, Harwood SJ, Caroll RG, Morrissey MA: Pharmacokinetics of Indium-111-labeled B72.3 monoclonal antibody in colorectal cancer patients. J Nucl Med 33:498, 1992
24. Koren HL, Handwerger BS, Wunderlich JR: Identification of macrophage-like characteristics in a cultured murine tumor line. J Immunol 114:894, 1975
25. Brailly H, Montero-Julian FA, Zuber CE, Flavetta S, Grassi J, Houssiau F, Van Snick J: Total interleukin-6 in plasma measured by immunoassay. Clin Chem 40:116, 1994
26. Dinarello CA: Anti-cytokine strategies. Eur Cytokine Network 3:7, 1992
27. Henderson B, Blake S: Therapeutic potential of cytokine manipulation. Trends Pharmacol Sci 13:145, 1992
28. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau G, Piguet PF, Pointaire P, Vassali P, Loetscher H: Recombinant soluble tumor necrosis factor receptor proteins protect mice from lypopolysaccharide-induced lethality. Eur J Immunol 22:2883, 1991
29. Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH: Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 88:10535, 1991
30. Castell JV, Geiger T, Gross V, Andus T, Walter E, Hirano T, Kishimoto T, Heinrich PC: Plasma clearance, organ distribution and target cells of interleukin 6/hepatocyte-stimulating-factor in the rat. Eur J Biochem 177:357, 1988
31. Castell J, Klapproth J, Gross V, Walter E, Andus T, Snyers L, Content J, Heinrich PC: Fate of interleukin-6 in the rat; involvement of skin in the catabolism. Eur J Biochem 189:113, 1990
32. Heremans H, Dillen C, Put W, VanDamme J, Billiau A: Protective effect of anti-interleukin (IL-6)-antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur J Immunol 22:2395, 1992
33. Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Maliszewski CR: Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 150:2717, 1993
34. Tomlinson A, Ziltener HJ: Enhancement of the biological effects of interleukin-3 in vivo by anti-interleukin-3 antibodies. Blood 82:1133, 1993
35. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR: Anti-cytokine antibodies as carrier proteins: Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 151:1235, 1993
36. Segal DM, Hurwitz E: Dimers and trimers of Immunoglobulin G covalently cross-linked by a bivalent affinity label. Biochemistry 15:5253, 1976
37. Segal DM, Hurwitz E: Binding of affinity cross-linked oligomers of IgG to cells bearing Fc receptors. J Immunol 118:1338, 1977
38. Dower SK, DeLisi C, Titus JA, Segal DM: Mechanism of binding of multivalent immune complexes to Fc receptors. 1. Equilibrium binding. Biochemistry 22:6326, 1981
39. Dower SK, Titus JA, DeLisi C, Segal DM: Mechanism of binding of multivalent immune complexes to Fc receptors. 2. Kinetics of binding. Biochemistry 22:6335, 1981
40. Segal DM, Dower SK, Titus JA: The role of non-immune IgG in controlling IgG-mediated effector functions. Mol Immunol 22:1177, 1983
41. Plotz PH, Kimberly RP, Guyer RL, Segal DM: Stable model immune complexes produced by bivalent affinity labeling haptens: In vivo survival. Mol Immunol 16:722, 1979
42. LeDoussal JM, Martin M, Gautherot E, Delaage M, Barbet J: In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 30:1358, 1989
43. LeDoussal JM, Gautherot E, Martin M, Barbet J, Delaage M: Enhanced in vivo targeting of an assymmetric bivalent hapten to double-antigen positive mouse B cells with monoclonal antibody conjugate cocktails. J Immunol 146:169, 1991
44. Benacerraf B, Sebestyen M, Cooper NS: The clearance of antigen-antibody complexes from the blood by the reticulo-endothelial system. J Immunol 82:131, 1959
45. Isaacs JD, Clark MR, Greenwood J, Waldmann H: Therapy with monoclonal antibodies: An in vivo model for the assessment of therapeutic potential. J Immunol 148:3062, 1992
46. Winter G, Milstein C: Man-made antibodies. Nature 349:293, 1991
47. Fridman WH, Bonnerot C, Daeron M, Amigorena S, Teillaud JL, Sautes C: Structural bases of Fc-gamma receptor functions. Immunol Rev 125:49, 1992
48. Lambert PH, Dixon FJ, Zubler RH, Agnello V, Cambiaso C, Casali D, Clark J, Cowdery JS, McDuffie FC, Hay FC, Mc Lennan ICM, Masoon P, Muller-Eberhard HJ, Peuttinen K, Smith M, Tappeiner G, Theofilopoulos AN, Verroust P: A WHO collaborative study for the evaluation of eighteen methods for the detecting immune complexes in serum. J Clin Lab Immunol 1:1, 1978
49. Lu Z-Y, Brailly H, Rossi JF, Wijdenes J, Bataille R, Klein B: Overall interleukin-6 production exceeds 7 mg/day during gram-negative sepsis. Cytokine 5:578, 1994